SlideShare une entreprise Scribd logo
1  sur  27
Télécharger pour lire hors ligne
Advancing Pain Relief, Preventing Abuse
Francis S. Collins, M.D., Ph.D.
Director, National Institutes of Health
National Rx Drug Abuse Summit
April 22, 2014
“Science in pursuit of fundamental
knowledge about the nature and
behavior of living systems
and the application of that
knowledge to extend healthy life
and reduce illness and disability.”
...
NIH: Steward of Medical and Behavioral
Research for the Nation
NIH: Advancing Pain Relief;
Preventing Abuse of Pain Relievers
  NIH supports wide array of programs and projects that
–  Enhance our understanding and treatment of pain
–  Improve our ability to monitor and prevent abuse of pain
relievers
  Examples include:
–  NIH Pain Consortium
–  “Monitoring the Future” study
–  Supporting research to curb
epidemic of opioid abuse
NIH Pain Consortium
Centers of Excellence in Pain Education
12 CoEPEs in 9 states, >100 schools
“Monitoring the Future”
  Survey measures drug, alcohol, and cigarette use and
related attitudes among adolescent students nationwide
–  Started in 1975
–  Conducted at the University of Michigan
–  Supported by NIH’s National Institute on
Drug Abuse (NIDA)
  2013 survey included 41,675 students
from 389 public and private schools
Percent of Students Reporting Nonmedical Use
of Vicodin in Past Year, by Grade
0
5
10
15
20
02 03 04 05 06 07 08 09 10 11 12 13
8th Grade 10th Grade 12th Grade
SOURCE: University of Michigan, 2013 Monitoring the Future Study
*Denotes significant difference between 2012 and 2013
*
Year
Percent of Students Reporting Nonmedical Use
of OxyContin in Past Year, by Grade
0
5
10
15
20
02 03 04 05 06 07 08 09 10 11 12 13
8th Grade 10th Grade 12th Grade
SOURCE: University of Michigan, 2013 Monitoring the Future Study
Year
Research: Finding New Responses to
Opioid Abuse
  Develop abuse-resistant drug formulations
  Devise user-friendly methods of antidote (naloxone)
administration
  Create mHealth interventions to help prevent opiate
overdose
  Produce new immunotherapies to treat addiction
Abuse-Resistant Drug Formulations:
Prodrugs
  Problem: changing method of taking opioids – i.e.,
crushing, injecting – increases euphoria; abuse
  Challenge: develop drugs that resist tampering; abuse
  Research response: oxycodone prodrug
–  Prodrugs: inactive compounds metabolized in the body to
produce active drug
–  NIH-supported Signature Therapeutics’ Bio-MD™ opioid prodrug
•  Resists extraction, tampering
•  2 prodrug types, for:
-  Hydromorphone
-  Oxycodone: priority
Abuse-Resistant Drug Formulations:
Oxycodone Prodrug
  Two-step activation process in the body
–  Taken orally, bioactivation by trypsin in GI tract
–  Cyclization release reaction
  Without activation, very little active opioid released
  NIH support:
–  NIDA
–  National Center for Advancing Translational Sciences’ “Bridging
Interventional Development Gaps” (BrIDGs) program
•  Supports application to FDA
User-Friendly Antidote Administration:
Naloxone
  Opioid overdose antidote: naloxone
–  Effective: reversed >10,000 overdose cases, 1996–2010*
–  Until recently, only available in injectable formulation
•  Practically, limited use to emergency medical personnel
  New formulation, Evzio, approved April 3, 2014
–  Hand-held auto-injector quickly delivers single dose
–  Facilitates use by family members, caregivers
  Simpler systems could expand availability even further
–  NIH/NIDA supporting development of intranasal delivery systems
*Centers for Disease Control and Prevention
User-Friendly Antidote Administration:
NIH-Supported Naloxone Nasal Sprays
AntiOp
  Developing single-dose, disposable nasal spray
–  Combines proven nasal spray device with
stable, concentrated, specially-formulated
naloxone solution
–  Investigational New Drug (IND) application
filed with FDA in 2012
–  Could be on the market ~18 months
Lightlake Therapeutics
  Conducting clinical trials with intranasal naloxone for
treatment of binge eating disorder
–  Applying technology to treatment of opioid overdose
–  Clinical trials began last fall
mHealth Interventions May Help Prevent
Opiate Overdose
Wireless Sensors
•  Respiration
•  Oximeter
•  Arrhythmias
Naloxone Delivery
•  Automatic
•  Patient
•  Third party
Alarm
•  Set up delivery
•  Alert patient
•  Alert third party
A Shift from Abuse of Prescription Pain
Relievers to Heroin
Cicero TJ et al. N Engl J Med 2012;367:187-189.
A recent increase in heroin use accompanied a downward trend in
OxyContin abuse – following introduction of an abuse-deterrent
formulation of OxyContin.
Antibodies reduce amount of drug in the brain
Capillary
Blood Flow
Brain
Immunotherapies to Treat Addiction:
Vaccines
Targets drugs,
not receptors
Capillary
Blood Flow
Brain
Antibodies
Vaccine
Binding
sites
  Vaccines using immune molecules to diminish effects of
abused drugs have been developed
  Heroin vaccine development trickier
–  Heroin is metabolized into many substances –
each with psychoactive effects
  NIH-supported researchers used dynamic approach to
develop heroin vaccine
–  Targets not only heroin, but chemicals into which it degrades
  Recent tests promising
  George Koob, co-PI, now at NIH….
Immunotherapies to Treat Addiction:
Heroin Vaccine
Learning the Language of the Brain
New Insights on the Horizon?
“The Next Great American Project”
BRAIN Buzz 2014
Tue gs collins
Tue gs collins
2013 Monitoring the Future Study
Prevalence of Past Year Drug Use Among 12th graders
Drug Prev. Drug Prev.
Alcohol 62.0 Sedatives* 4.8
Marijuana/Hashish 36.4 Tranquilizers* 4.6
Hookah 21.4 Hallucinogens 4.5
Small cigars 20.4 MDMA (Ecstasy) 4.0
Amphetamines* 8.7 Hall other than LSD 3.7
Synthetic Marijuana 7.9 OxyContin* 3.6
Snus 7.7 Salvia 3.4
Adderall* 7.4 Cocaine (any form) 2.6
Narcotics o/t Heroin* 7.1 Inhalants 2.5
Vicodin* 5.3 Ritalin* 2.3
Cough Medicine* 5.0 LSD 2.2
* Nonmedical use Categories not mutually exclusive
Percent of Students Reporting Use of
Heroin in Past Year, by Grade
0
5
10
15
20
95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13
8th Grade 10th Grade 12th Grade
Year
SOURCE: University of Michigan, 2013 Monitoring the Future Study
Percent of High School Seniors Reporting Use
of Narcotics Other than Heroin
0
5
10
15
20
91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12
12th grade
SOURCE: University of Michigan, 2013 Monitoring the Future Study
Year
Percent Reporting Narcotics Other Than Heroin
as ‘fairly easy’ or ‘very easy’ to Obtain, by Grade
0
20
40
60
80
100
92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13
8th Grade 10th Grade 12th Grade
SOURCE: University of Michigan, 2013 Monitoring the Future Study
*Denotes significant difference between 2012 and 2013
*
•  Collaborator: Signature Therapeutics (Palo Alto, CA)
•  Compound: Oral prodrug formulation of oxycodone
  Tamper-resistant - Common methods of tampering do not
release appreciable amounts of the active opioid.
•  Novel Project Intake Model
  MOU between NIDA and NCATS
  3-way CRADA including Signature
•  Pending BrIDGs Studies:
  GMP synthesis
  Packaging of drug supply
  PK/ADME and GLP toxicology studies
•  IND Goal: End of 2014
Binding Site
Capillary
Blood Flow
Brain
Antibodies	

VACCINE	

Antibodies Can Reduce Brain Concentrations
Immunotherapies for Addiction Treatment
(i.e., Vaccines)
Capillary
Blood Flow
Brain
Targeting the drugs,
not the receptors
##p<0.01, ###p<0.001, significant reduction
of analgesia vs. Control/KLH group,
### p<0.001, significant reduction of
analgesia vs. Control/KLH group
Heroin	
  1	
  mg/kg,	
  
	
  s.c.	
  
30	
  min	
  
Hot Plate Test
The Vaccine(s)
Immunotherapies to Treat Addiction:
Heroin Vaccines
*K.D. Janda & G.F. Koob Laboratories at TSRI
Dr. Koob now at NIH

Contenu connexe

Tendances

Opioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHSc
Opioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHScOpioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHSc
Opioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHScUniversity of Michigan Injury Center
 
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldRx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldOPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...University of Michigan Injury Center
 
Expanding the Understanding of Risks Associated with Opioids as Well as Strat...
Expanding the Understanding of Risks Associated with Opioids as Well as Strat...Expanding the Understanding of Risks Associated with Opioids as Well as Strat...
Expanding the Understanding of Risks Associated with Opioids as Well as Strat...University of Michigan Injury Center
 
Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...
Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...
Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...University of Michigan Injury Center
 
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderRx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderOPUNITE
 
Rx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_groupRx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_groupOPUNITE
 
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesRx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesOPUNITE
 
Tx 3 hill shuman_oliver
Tx 3 hill shuman_oliverTx 3 hill shuman_oliver
Tx 3 hill shuman_oliverOPUNITE
 
Improving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPH
Improving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPHImproving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPH
Improving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPHUniversity of Michigan Injury Center
 
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...University of Michigan Injury Center
 
Wed vs progressive
Wed vs progressiveWed vs progressive
Wed vs progressiveOPUNITE
 
Rx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisRx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisOPUNITE
 
Preventing Prescription Opioid Overdoses: Changing Patients' Risky Opioid Us...
Preventing Prescription Opioid Overdoses: Changing Patients'  Risky Opioid Us...Preventing Prescription Opioid Overdoses: Changing Patients'  Risky Opioid Us...
Preventing Prescription Opioid Overdoses: Changing Patients' Risky Opioid Us...University of Michigan Injury Center
 
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaView only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaOPUNITE
 
Revised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupontRevised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupontOPUNITE
 

Tendances (20)

Opioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHSc
Opioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHScOpioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHSc
Opioid Surveillance and Policy: A Canadian Perspective by Tara Gomes, MHSc
 
Naloxone for Opioid Safety by Phillip Coffin, MD, MIA
Naloxone for Opioid Safety by Phillip Coffin, MD, MIANaloxone for Opioid Safety by Phillip Coffin, MD, MIA
Naloxone for Opioid Safety by Phillip Coffin, MD, MIA
 
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldRx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
 
Expanding the Understanding of Risks Associated with Opioids as Well as Strat...
Expanding the Understanding of Risks Associated with Opioids as Well as Strat...Expanding the Understanding of Risks Associated with Opioids as Well as Strat...
Expanding the Understanding of Risks Associated with Opioids as Well as Strat...
 
Monica Bharel, "Addressing the Opioid Epidemic through a Public Health Lens"
Monica Bharel, "Addressing the Opioid Epidemic through a Public Health Lens"Monica Bharel, "Addressing the Opioid Epidemic through a Public Health Lens"
Monica Bharel, "Addressing the Opioid Epidemic through a Public Health Lens"
 
Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...
Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...
Responding to the Opioid Problem: New Directions in Research by Jack B. Stein...
 
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderRx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
 
Rx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_groupRx16 vs ukhealthcare_800_group
Rx16 vs ukhealthcare_800_group
 
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesRx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
 
Tx 3 hill shuman_oliver
Tx 3 hill shuman_oliverTx 3 hill shuman_oliver
Tx 3 hill shuman_oliver
 
Improving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPH
Improving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPHImproving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPH
Improving Opioid Prescribing in VA Primary Care by Erin E. Krebs, MD, MPH
 
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
 
Wed vs progressive
Wed vs progressiveWed vs progressive
Wed vs progressive
 
Rx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willisRx16 heroin tues_200_1_allen-harocopos_2willis
Rx16 heroin tues_200_1_allen-harocopos_2willis
 
Rita Nieves, "Boston Public Health Commission: A City's Health Department Per...
Rita Nieves, "Boston Public Health Commission: A City's Health Department Per...Rita Nieves, "Boston Public Health Commission: A City's Health Department Per...
Rita Nieves, "Boston Public Health Commission: A City's Health Department Per...
 
Preventing Prescription Opioid Overdoses: Changing Patients' Risky Opioid Us...
Preventing Prescription Opioid Overdoses: Changing Patients'  Risky Opioid Us...Preventing Prescription Opioid Overdoses: Changing Patients'  Risky Opioid Us...
Preventing Prescription Opioid Overdoses: Changing Patients' Risky Opioid Us...
 
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaView only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
 
Revised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupontRevised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupont
 

En vedette

Opiate addiction treatment center
Opiate addiction treatment centerOpiate addiction treatment center
Opiate addiction treatment centermishelenoare
 
Hw499 week 2 lecture notes
Hw499 week 2 lecture notesHw499 week 2 lecture notes
Hw499 week 2 lecture notesMariahJoyce
 
Preventing teen abuse of prescriptions and over the
Preventing teen abuse of prescriptions and over thePreventing teen abuse of prescriptions and over the
Preventing teen abuse of prescriptions and over theraynaandyailka
 
Leonard Young CORRECT
Leonard Young CORRECTLeonard Young CORRECT
Leonard Young CORRECTOPUNITE
 
Tue vs samhsa - harding
Tue vs   samhsa - hardingTue vs   samhsa - harding
Tue vs samhsa - hardingOPUNITE
 
Tue vs ameritox -yasko-brasika_de_george
Tue vs   ameritox -yasko-brasika_de_georgeTue vs   ameritox -yasko-brasika_de_george
Tue vs ameritox -yasko-brasika_de_georgeOPUNITE
 
Tue vs centpatico - van tassell
Tue vs   centpatico - van tassellTue vs   centpatico - van tassell
Tue vs centpatico - van tassellOPUNITE
 
Tuesday astho
Tuesday asthoTuesday astho
Tuesday asthoOPUNITE
 
Tuesday partnership
Tuesday partnershipTuesday partnership
Tuesday partnershipOPUNITE
 
Tue vs ondcp spitznas
Tue vs   ondcp spitznasTue vs   ondcp spitznas
Tue vs ondcp spitznasOPUNITE
 
Tue gs mc cance-katz
Tue gs mc cance-katzTue gs mc cance-katz
Tue gs mc cance-katzOPUNITE
 
Peter Kreiner
Peter KreinerPeter Kreiner
Peter KreinerOPUNITE
 
Tue gs botticelli
Tue gs botticelliTue gs botticelli
Tue gs botticelliOPUNITE
 
Ph 4 rannizzisi
Ph 4 rannizzisiPh 4 rannizzisi
Ph 4 rannizzisiOPUNITE
 

En vedette (15)

Opiate addiction treatment center
Opiate addiction treatment centerOpiate addiction treatment center
Opiate addiction treatment center
 
Hw499 week 2 lecture notes
Hw499 week 2 lecture notesHw499 week 2 lecture notes
Hw499 week 2 lecture notes
 
Dayton - opiate prescription abuse in utah
Dayton - opiate prescription abuse in utahDayton - opiate prescription abuse in utah
Dayton - opiate prescription abuse in utah
 
Preventing teen abuse of prescriptions and over the
Preventing teen abuse of prescriptions and over thePreventing teen abuse of prescriptions and over the
Preventing teen abuse of prescriptions and over the
 
Leonard Young CORRECT
Leonard Young CORRECTLeonard Young CORRECT
Leonard Young CORRECT
 
Tue vs samhsa - harding
Tue vs   samhsa - hardingTue vs   samhsa - harding
Tue vs samhsa - harding
 
Tue vs ameritox -yasko-brasika_de_george
Tue vs   ameritox -yasko-brasika_de_georgeTue vs   ameritox -yasko-brasika_de_george
Tue vs ameritox -yasko-brasika_de_george
 
Tue vs centpatico - van tassell
Tue vs   centpatico - van tassellTue vs   centpatico - van tassell
Tue vs centpatico - van tassell
 
Tuesday astho
Tuesday asthoTuesday astho
Tuesday astho
 
Tuesday partnership
Tuesday partnershipTuesday partnership
Tuesday partnership
 
Tue vs ondcp spitznas
Tue vs   ondcp spitznasTue vs   ondcp spitznas
Tue vs ondcp spitznas
 
Tue gs mc cance-katz
Tue gs mc cance-katzTue gs mc cance-katz
Tue gs mc cance-katz
 
Peter Kreiner
Peter KreinerPeter Kreiner
Peter Kreiner
 
Tue gs botticelli
Tue gs botticelliTue gs botticelli
Tue gs botticelli
 
Ph 4 rannizzisi
Ph 4 rannizzisiPh 4 rannizzisi
Ph 4 rannizzisi
 

Similaire à Tue gs collins

Rx misuse among ya including pain relievers
Rx misuse among ya including pain relieversRx misuse among ya including pain relievers
Rx misuse among ya including pain relieverscindylibrary
 
At risk young people and drug abuse in WA
At risk young people and drug abuse in WAAt risk young people and drug abuse in WA
At risk young people and drug abuse in WAPatricia Gorman
 
EVERFI Webinar: Evidence Based Prescription Drugs Program
EVERFI Webinar: Evidence Based Prescription Drugs ProgramEVERFI Webinar: Evidence Based Prescription Drugs Program
EVERFI Webinar: Evidence Based Prescription Drugs ProgramMichele Collu
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverOPUNITE
 
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
CDC 2018-Evidence-Based-Strategies For Preventing Opioid OverdoseCDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
CDC 2018-Evidence-Based-Strategies For Preventing Opioid OverdoseCassondra Turner McArthur
 
Identification of substance abuse among medical students in a Nigerian Univer...
Identification of substance abuse among medical students in a Nigerian Univer...Identification of substance abuse among medical students in a Nigerian Univer...
Identification of substance abuse among medical students in a Nigerian Univer...BRNSSPublicationHubI
 
Unit 3 drug utilization research (6hrs) march 12 2021
Unit 3 drug utilization research (6hrs) march 12 2021Unit 3 drug utilization research (6hrs) march 12 2021
Unit 3 drug utilization research (6hrs) march 12 2021University of Gondar
 
A systematic review_on_the_use_of_psychosocial.4
A systematic review_on_the_use_of_psychosocial.4A systematic review_on_the_use_of_psychosocial.4
A systematic review_on_the_use_of_psychosocial.4Paul Coelho, MD
 
Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)
Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)
Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)oyepata
 
Knowledge and practice of unused medicines disposal among patients and pharma...
Knowledge and practice of unused medicines disposal among patients and pharma...Knowledge and practice of unused medicines disposal among patients and pharma...
Knowledge and practice of unused medicines disposal among patients and pharma...BRNSSPublicationHubI
 
Policy recommendations for improved medication adherence in Europe: the ABC P...
Policy recommendations for improved medication adherence in Europe: the ABC P...Policy recommendations for improved medication adherence in Europe: the ABC P...
Policy recommendations for improved medication adherence in Europe: the ABC P...Global Risk Forum GRFDavos
 
Presentation (1)-1.pptx
Presentation (1)-1.pptxPresentation (1)-1.pptx
Presentation (1)-1.pptxJaibhagwan47
 
Pharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reactionPharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reactionRahul Bhati
 
Tx 1 dupont
Tx 1 dupontTx 1 dupont
Tx 1 dupontOPUNITE
 

Similaire à Tue gs collins (20)

Rx misuse among ya including pain relievers
Rx misuse among ya including pain relieversRx misuse among ya including pain relievers
Rx misuse among ya including pain relievers
 
At risk young people and drug abuse in WA
At risk young people and drug abuse in WAAt risk young people and drug abuse in WA
At risk young people and drug abuse in WA
 
EVERFI Webinar: Evidence Based Prescription Drugs Program
EVERFI Webinar: Evidence Based Prescription Drugs ProgramEVERFI Webinar: Evidence Based Prescription Drugs Program
EVERFI Webinar: Evidence Based Prescription Drugs Program
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
 
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
CDC 2018-Evidence-Based-Strategies For Preventing Opioid OverdoseCDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
CDC 2018-Evidence-Based-Strategies For Preventing Opioid Overdose
 
Identification of substance abuse among medical students in a Nigerian Univer...
Identification of substance abuse among medical students in a Nigerian Univer...Identification of substance abuse among medical students in a Nigerian Univer...
Identification of substance abuse among medical students in a Nigerian Univer...
 
Ppt4 (1)
Ppt4 (1)Ppt4 (1)
Ppt4 (1)
 
Unit 3 drug utilization research (6hrs) march 12 2021
Unit 3 drug utilization research (6hrs) march 12 2021Unit 3 drug utilization research (6hrs) march 12 2021
Unit 3 drug utilization research (6hrs) march 12 2021
 
A systematic review_on_the_use_of_psychosocial.4
A systematic review_on_the_use_of_psychosocial.4A systematic review_on_the_use_of_psychosocial.4
A systematic review_on_the_use_of_psychosocial.4
 
Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)
Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)
Stages of drug development by Dr Joseph Oyepata Simeon (Ph.D)
 
November 2018 Directors Meeting - UofSC Division of Student Affairs and Acade...
November 2018 Directors Meeting - UofSC Division of Student Affairs and Acade...November 2018 Directors Meeting - UofSC Division of Student Affairs and Acade...
November 2018 Directors Meeting - UofSC Division of Student Affairs and Acade...
 
Opioid Use
Opioid Use Opioid Use
Opioid Use
 
Knowledge and practice of unused medicines disposal among patients and pharma...
Knowledge and practice of unused medicines disposal among patients and pharma...Knowledge and practice of unused medicines disposal among patients and pharma...
Knowledge and practice of unused medicines disposal among patients and pharma...
 
drugs and development
drugs and development drugs and development
drugs and development
 
Policy recommendations for improved medication adherence in Europe: the ABC P...
Policy recommendations for improved medication adherence in Europe: the ABC P...Policy recommendations for improved medication adherence in Europe: the ABC P...
Policy recommendations for improved medication adherence in Europe: the ABC P...
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Presentation (1)-1.pptx
Presentation (1)-1.pptxPresentation (1)-1.pptx
Presentation (1)-1.pptx
 
Pharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reactionPharmacovigilance & Adverse drug reaction
Pharmacovigilance & Adverse drug reaction
 
Sk. Shafiulla
Sk. ShafiullaSk. Shafiulla
Sk. Shafiulla
 
Tx 1 dupont
Tx 1 dupontTx 1 dupont
Tx 1 dupont
 

Plus de OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynoteOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerOPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceOPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerOPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_groupOPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldOPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioOPUNITE
 

Plus de OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 

Dernier

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 

Dernier (20)

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 

Tue gs collins

  • 1. Advancing Pain Relief, Preventing Abuse Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health National Rx Drug Abuse Summit April 22, 2014
  • 2. “Science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce illness and disability.” ... NIH: Steward of Medical and Behavioral Research for the Nation
  • 3. NIH: Advancing Pain Relief; Preventing Abuse of Pain Relievers   NIH supports wide array of programs and projects that –  Enhance our understanding and treatment of pain –  Improve our ability to monitor and prevent abuse of pain relievers   Examples include: –  NIH Pain Consortium –  “Monitoring the Future” study –  Supporting research to curb epidemic of opioid abuse
  • 4. NIH Pain Consortium Centers of Excellence in Pain Education 12 CoEPEs in 9 states, >100 schools
  • 5. “Monitoring the Future”   Survey measures drug, alcohol, and cigarette use and related attitudes among adolescent students nationwide –  Started in 1975 –  Conducted at the University of Michigan –  Supported by NIH’s National Institute on Drug Abuse (NIDA)   2013 survey included 41,675 students from 389 public and private schools
  • 6. Percent of Students Reporting Nonmedical Use of Vicodin in Past Year, by Grade 0 5 10 15 20 02 03 04 05 06 07 08 09 10 11 12 13 8th Grade 10th Grade 12th Grade SOURCE: University of Michigan, 2013 Monitoring the Future Study *Denotes significant difference between 2012 and 2013 * Year
  • 7. Percent of Students Reporting Nonmedical Use of OxyContin in Past Year, by Grade 0 5 10 15 20 02 03 04 05 06 07 08 09 10 11 12 13 8th Grade 10th Grade 12th Grade SOURCE: University of Michigan, 2013 Monitoring the Future Study Year
  • 8. Research: Finding New Responses to Opioid Abuse   Develop abuse-resistant drug formulations   Devise user-friendly methods of antidote (naloxone) administration   Create mHealth interventions to help prevent opiate overdose   Produce new immunotherapies to treat addiction
  • 9. Abuse-Resistant Drug Formulations: Prodrugs   Problem: changing method of taking opioids – i.e., crushing, injecting – increases euphoria; abuse   Challenge: develop drugs that resist tampering; abuse   Research response: oxycodone prodrug –  Prodrugs: inactive compounds metabolized in the body to produce active drug –  NIH-supported Signature Therapeutics’ Bio-MD™ opioid prodrug •  Resists extraction, tampering •  2 prodrug types, for: -  Hydromorphone -  Oxycodone: priority
  • 10. Abuse-Resistant Drug Formulations: Oxycodone Prodrug   Two-step activation process in the body –  Taken orally, bioactivation by trypsin in GI tract –  Cyclization release reaction   Without activation, very little active opioid released   NIH support: –  NIDA –  National Center for Advancing Translational Sciences’ “Bridging Interventional Development Gaps” (BrIDGs) program •  Supports application to FDA
  • 11. User-Friendly Antidote Administration: Naloxone   Opioid overdose antidote: naloxone –  Effective: reversed >10,000 overdose cases, 1996–2010* –  Until recently, only available in injectable formulation •  Practically, limited use to emergency medical personnel   New formulation, Evzio, approved April 3, 2014 –  Hand-held auto-injector quickly delivers single dose –  Facilitates use by family members, caregivers   Simpler systems could expand availability even further –  NIH/NIDA supporting development of intranasal delivery systems *Centers for Disease Control and Prevention
  • 12. User-Friendly Antidote Administration: NIH-Supported Naloxone Nasal Sprays AntiOp   Developing single-dose, disposable nasal spray –  Combines proven nasal spray device with stable, concentrated, specially-formulated naloxone solution –  Investigational New Drug (IND) application filed with FDA in 2012 –  Could be on the market ~18 months Lightlake Therapeutics   Conducting clinical trials with intranasal naloxone for treatment of binge eating disorder –  Applying technology to treatment of opioid overdose –  Clinical trials began last fall
  • 13. mHealth Interventions May Help Prevent Opiate Overdose Wireless Sensors •  Respiration •  Oximeter •  Arrhythmias Naloxone Delivery •  Automatic •  Patient •  Third party Alarm •  Set up delivery •  Alert patient •  Alert third party
  • 14. A Shift from Abuse of Prescription Pain Relievers to Heroin Cicero TJ et al. N Engl J Med 2012;367:187-189. A recent increase in heroin use accompanied a downward trend in OxyContin abuse – following introduction of an abuse-deterrent formulation of OxyContin.
  • 15. Antibodies reduce amount of drug in the brain Capillary Blood Flow Brain Immunotherapies to Treat Addiction: Vaccines Targets drugs, not receptors Capillary Blood Flow Brain Antibodies Vaccine Binding sites
  • 16.   Vaccines using immune molecules to diminish effects of abused drugs have been developed   Heroin vaccine development trickier –  Heroin is metabolized into many substances – each with psychoactive effects   NIH-supported researchers used dynamic approach to develop heroin vaccine –  Targets not only heroin, but chemicals into which it degrades   Recent tests promising   George Koob, co-PI, now at NIH…. Immunotherapies to Treat Addiction: Heroin Vaccine
  • 17. Learning the Language of the Brain New Insights on the Horizon? “The Next Great American Project”
  • 21. 2013 Monitoring the Future Study Prevalence of Past Year Drug Use Among 12th graders Drug Prev. Drug Prev. Alcohol 62.0 Sedatives* 4.8 Marijuana/Hashish 36.4 Tranquilizers* 4.6 Hookah 21.4 Hallucinogens 4.5 Small cigars 20.4 MDMA (Ecstasy) 4.0 Amphetamines* 8.7 Hall other than LSD 3.7 Synthetic Marijuana 7.9 OxyContin* 3.6 Snus 7.7 Salvia 3.4 Adderall* 7.4 Cocaine (any form) 2.6 Narcotics o/t Heroin* 7.1 Inhalants 2.5 Vicodin* 5.3 Ritalin* 2.3 Cough Medicine* 5.0 LSD 2.2 * Nonmedical use Categories not mutually exclusive
  • 22. Percent of Students Reporting Use of Heroin in Past Year, by Grade 0 5 10 15 20 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 8th Grade 10th Grade 12th Grade Year SOURCE: University of Michigan, 2013 Monitoring the Future Study
  • 23. Percent of High School Seniors Reporting Use of Narcotics Other than Heroin 0 5 10 15 20 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 12th grade SOURCE: University of Michigan, 2013 Monitoring the Future Study Year
  • 24. Percent Reporting Narcotics Other Than Heroin as ‘fairly easy’ or ‘very easy’ to Obtain, by Grade 0 20 40 60 80 100 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 8th Grade 10th Grade 12th Grade SOURCE: University of Michigan, 2013 Monitoring the Future Study *Denotes significant difference between 2012 and 2013 *
  • 25. •  Collaborator: Signature Therapeutics (Palo Alto, CA) •  Compound: Oral prodrug formulation of oxycodone   Tamper-resistant - Common methods of tampering do not release appreciable amounts of the active opioid. •  Novel Project Intake Model   MOU between NIDA and NCATS   3-way CRADA including Signature •  Pending BrIDGs Studies:   GMP synthesis   Packaging of drug supply   PK/ADME and GLP toxicology studies •  IND Goal: End of 2014
  • 26. Binding Site Capillary Blood Flow Brain Antibodies VACCINE Antibodies Can Reduce Brain Concentrations Immunotherapies for Addiction Treatment (i.e., Vaccines) Capillary Blood Flow Brain Targeting the drugs, not the receptors
  • 27. ##p<0.01, ###p<0.001, significant reduction of analgesia vs. Control/KLH group, ### p<0.001, significant reduction of analgesia vs. Control/KLH group Heroin  1  mg/kg,    s.c.   30  min   Hot Plate Test The Vaccine(s) Immunotherapies to Treat Addiction: Heroin Vaccines *K.D. Janda & G.F. Koob Laboratories at TSRI Dr. Koob now at NIH